Comparison 8. Efficacy ‐ febuxostat 240 mg/day versus allopurinol 300 mg/day.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Incidence of gout flares	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 28 weeks	1	402	Risk Ratio (M‐H, Fixed, 95% CI)	2.26 [1.72, 2.98]
2 Serum uric acid <6.0 mg/dL at final visit	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 28 weeks	1	291	Risk Ratio (M‐H, Fixed, 95% CI)	2.30 [1.94, 2.73]
3 Change in serum uric acid concentration from baseline at final visit	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.1 8 weeks	1	402	Mean Difference (IV, Fixed, 95% CI)	‐3.35 [‐3.61, ‐3.09]